JEMPERLI — GLAXOSMITHKLINE, approved 2024-08-01 (BLA761174).
1,198 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.